MeMed Diagnostics, une entreprise basée à Haïfa qui développe des kits pour surveiller l’état immunitaire du corps humain, a annoncé qu’elle allait s’associer à l’entreprise de diagnostic italienne DiaSorin pour commercialiser un test capable de distinguer infections bactérienne et virale.
C’est le premier des tests de la startup israélienne à être commercialisé, et c’est également le premier partenariat commercial dans le domaine du diagnostic de la réponse immunitaire de l’hôte, a fait savoir MeMed dans un communiqué mardi. (Times of Israël)
DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). The company is a constituent of the FTSE Italia Mid Cap index.
In February and March 2020, from the novel coronavirus pandemia, DiaSorin has devised and developed a molecular diagnostic test intended to detect all the currently known variants of the COVID-19. The test enables sample-to-answer results within less than 60 minutes compared to the 5–7 hours currently necessary to report patient results.
On 7 April 2020, DiaSorin announced the development of a new IgG CLIA test to identify antibodies against SARS-CoV-2 antibody test, that allows to detect antibodies directed against the virus in patients’ serum samples, identifying subjects who have developed an immune response to the virus, offering a tool for epidemiologic assessment of populations. On 25 April 2020, DiaSorin received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for COVID-19.
